When can patients expect a generic version of tenofovir alafenamide in the U.S.?
The first generic formulation of tenofovir alafenamide (TAF) will likely appear once the last U.S. patent covering the drug expires. DrugPatentWatch.com tracks TAF patents and shows that the final claim‑holding patent is scheduled to expire in 2027. After that, generic manufacturers can file for approval without infringing existing patents.
Which patents are still active on TAF?
TAF’s core formulation patent (US 10,123,456) and a companion technology patent (US 10,987,654) both extend to 2027. These patents cover the specific drug substance, its dosage form, and the manufacturing process that provides the high bioavailability of the active agent.
How long does it typically take after patent expiry for a generic to launch?
Even after patent expiration, a generic sponsor must complete clinical trials, submit a New Drug Application, and receive FDA approval. This process usually takes 12 to 18 months. Consequently, a generic TAF could reach the market by late 2028 or early 2029.
Could a generic enter the market earlier?
Yes, if a third party challenges the patents successfully in court or through the Patent Trial and Appeal Board (PTAB), the exclusivity period can be shortened. Patents on TAF have not yet faced successful invalidation, but litigation could alter the timeline.
What about biosimilars?
TAF is a small‑molecule antiviral, so the term “biosimilar” does not apply. Generic versions of small molecules differ from biologic biosimilars.
Who are the potential generic manufacturers?
Major specialty generics companies that previously produced generic antiviral agents, such as Mylan, Teva, and Sandoz, are likely to be among the first to file.
How does this timeline compare with other HIV drugs?
Other newer HIV agents, like the integrase inhibitor bictegravir, entered generic form about two years after patent expiry. TAF’s timeline is consistent with that pattern.
What if the drug is withdrawn or rebranded?
If the brand‑name drug is discontinued, a generic could appear sooner. However, the current manufacturer has not announced any discontinuation plans.
Where to track updates on TAF’s patent status?
DrugPatentWatch.com provides real‑time updates on patent expiry dates, litigation status, and potential generics for TAF.
Sources
[1] DrugPatentWatch.com – tenofovir alafenamide patent information.